CoHealth (Formerly Dash MD)

Belkins
CoHealth is a patient access platform delivered to patients in any healthcare setting. We capture patient attention through our personal health manager by partnering with health providers to create customized, digital care pathways for a variety of health related conditions. We then use patient attention to drive insights and value to our partners to promote organizational efficiencies and strategic decision making.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ABBVIE, AMGEN AND TAKEDA TAKE COLLABORATIVE EFFORTS TO TACKLE COVID-19

Fiercepharma | August 03, 2020

news image

The drug industry has come together in unprecedented collaborative efforts to tackle COVID-19. Now, as part of an R&D alliance, three big drugmakers are running a joint clinical trial to see whether their products can improve outcomes for severely ill patients. A recently launched clinical program, dubbed I-SPY, will test Amgen’s psoriasis med Otezla, Takeda’s hereditary angioedema therapy Firazyr and AbbVie’s experimental nonalcoholic steatohepatitis drug cenicriviroc to s...

Read More

RESEARCH

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma | November 30, 2020

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More

PHARMA TECH

TRANQUILMONEY RELEASES PHARMTRACKER FOR INDEPENDENT PHARMACIES, SMALL AND MEDIUM PHARMACY CHAINS

Tranquilmoney | December 28, 2020

news image

Tranquilmoney, Inc., an organization that oversaw drug store outsider case compromise for Costco Pharmacy for more than 20 years, has delivered an electronic adaptation of its product. Any drug store would now be able to join to PharmTrackerTM and begin utilizing the framework to handle their cases. Tranquilmoney has overseen over $1 billion per year in drug store receivables compromise with 100% compromise and 99.9% assortments. Industry guidelines of assortment are about 92.5%.<...

Read More

PHARMACY MARKET

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

news image

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More

Fiercepharma | August 03, 2020

news image

ABBVIE, AMGEN AND TAKEDA TAKE COLLABORATIVE EFFORTS TO TACKLE COVID-19

The drug industry has come together in unprecedented collaborative efforts to tackle COVID-19. Now, as part of an R&D alliance, three big drugmakers are running a joint clinical trial to see whether their products can improve outcomes for severely ill patients. A recently launched clinical program, dubbed I-SPY, will test Amgen’s psoriasis med Otezla, Takeda’s hereditary angioedema therapy Firazyr and AbbVie’s experimental nonalcoholic steatohepatitis drug cenicriviroc to s...

Read More

RESEARCH

Ascentage Pharma | November 30, 2020

news image

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More

PHARMA TECH

Tranquilmoney | December 28, 2020

news image

TRANQUILMONEY RELEASES PHARMTRACKER FOR INDEPENDENT PHARMACIES, SMALL AND MEDIUM PHARMACY CHAINS

Tranquilmoney, Inc., an organization that oversaw drug store outsider case compromise for Costco Pharmacy for more than 20 years, has delivered an electronic adaptation of its product. Any drug store would now be able to join to PharmTrackerTM and begin utilizing the framework to handle their cases. Tranquilmoney has overseen over $1 billion per year in drug store receivables compromise with 100% compromise and 99.9% assortments. Industry guidelines of assortment are about 92.5%.<...

Read More

PHARMACY MARKET

Eli Lilly and Company | August 25, 2021

news image

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More